The company is developing treatments for autism and substance use disorders tailored to patient subgroups identified by clinico-genomic signatures.

The approval in the second-line EGFR- and MET-altered setting was based on results from the SACHI trial, which compared Orpathys and Tagrisso against chemo.

NEW YORK – Bristol Myers Squibb on Friday said the US Food and Drug Administration approved label updates for its autologous CAR T-cell therapies Breyanzi (lisocabtagene maraleucel) and Abecma ...

NEW YORK – Allarity Therapeutics has begun dosing patients in a Phase II trial studying its dual PARP and WNT pathway inhibitor stenoparib in patients with advanced, recurrent, platinum-resistant or ...

NEW YORK – Politicians and healthcare administrators in Washington have recently spoken out against direct-to-consumer pharmaceutical advertising, but experts say the latest legislative attempt to ban ...

NEW YORK – Plus Therapeutics announced this week that it will relaunch the CNSide cerebrospinal fluid assay in the US this year, restoring access to a test for diagnosing and monitoring patients with ...

For selected applicants, the agency plans to cut review times down to one to two months and provide "tumor board-style" ...

UCLA-led investigators say additional research is needed into why guideline-recommended genetic testing remains low among ...

NEW YORK – A2 Biotherapeutics has treated the first solid tumor patient with its CAR T-cell therapy A2B395 in a Phase I/II clinical trial, the firm announced Thursday.. Agoura Hills, California-based ...